FDA Brief

Warning letters Drugs

FDA warning letter to

Maria E. De La Torre Silva, M.D.

MediumIssued Jul 27Posted Aug 4Center for Drug Evaluation and Research (CDER)

Clinical investigator Dr. Maria E. De La Torre Silva enrolled a subject in two drug trials and kept inadequate study-drug records.

What happened

FDA inspected the clinical site from June 26 to July 15, 2025, under its Bioresearch Monitoring Program and reviewed the inspection report, documents, and the investigator’s August 4, 2025 response. FDA found that a subject was simultaneously enrolled and randomized in another clinical investigation and received that study’s investigational drug while enrolled in the cited protocol, contrary to the protocol’s exclusion and prohibited-product requirements. FDA also found drug-accountability discrepancies for six subjects between self-reported doses, site records, electronic data capture records, and the physical condition of returned kits.

What FDA found

  1. The investigator failed to ensure the study was conducted according to the investigational plan because a subject was enrolled in another trial and received another investigational product during the study.

    21 CFR 312.60
  2. The investigator failed to maintain adequate records of study-drug disposition, including dates, quantity, and use by subjects, with discrepancies for six subjects.

    21 CFR 312.62(a)

What FDA wants

FDA asks the investigator to respond in writing within 15 business days describing actions taken to prevent similar violations and to establish procedures for any ongoing or future studies.

Who should pay attention

  • clinical trial sponsors using investigator sites
  • contract research organizations overseeing site compliance
  • investigators and site staff responsible for drug accountability

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Stephen J. Fallon, Ph.D.

    FDA warns clinical investigator Stephen J. Fallon, Ph.D. over consent and record failures in an HIV self-test study.

    High risk
  2. Pratik Doshi, M.D. / Alembic Pharmaceuticals Ltd.

    FDA warned investigator Dr. Pratik Doshi at Alembic's Vadodara site that a bioequivalence study consent form wrongly said nothing was experimental.

    High risk
  3. Jose M. Carpio, M.D.

    FDA warned clinical investigator Dr. Jose Carpio of Miami Lakes, FL, that trial subjects received less than the protocol-required dose of study drug.

    Medium
  4. Adnan Dahdul, MD

    FDA warns clinical investigator Dr. Adnan Dahdul over consent, eligibility and record failures in a biologics study.

    High risk